Literature DB >> 1560259

Brain metastases of malignant melanoma in interferon complete responders: clinical and radiological observations.

O Merimsky1, M Inbar, I Reider-Groswasser, S Chaitchik.   

Abstract

Three patients with metastatic malignant melanoma, 2 of whom were males with primary lesion on the shoulder, and a female with primary lesion on the ankle, with Clark's level III-IV, completely responded to interferon-DTIC, but failed in the brain. Radiologically, all the lesions were peripheral in location, and none showed any bleeding tendency. Clinically, these lesions seemed to be resistant to radiotherapy, chemotherapy or steroid treatment, and were the cause of death after a very short survival period. Interferon apparently is inactive against melanoma brain metastases, but does cause CNS symptoms. Because CNS metastases are sometimes the sole site of clinical relapse, and are frequently disabling, prophylactic cranial irradiation (PCI) needs to be studied in high risk patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560259     DOI: 10.1007/bf00172663

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  7 in total

Review 1.  The pharmacology and toxicology of the interferons: an overview.

Authors:  G J Mannering; L B Deloria
Journal:  Annu Rev Pharmacol Toxicol       Date:  1986       Impact factor: 13.820

2.  Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer. Potential benefit restricted to patients with complete response.

Authors:  S T Rosen; R W Makuch; A S Lichter; D C Ihde; M J Matthews; J D Minna; E Glatstein; P A Bunn
Journal:  Am J Med       Date:  1983-04       Impact factor: 4.965

3.  Late neurological complications after prophylactic cranial irradiation in patients with small-cell lung cancer: the Toronto experience.

Authors:  M Lishner; R Feld; D G Payne; U Sagman; J P Sculier; J F Pringle; J L Yeoh; W K Evans; F A Shepherd; E Maki
Journal:  J Clin Oncol       Date:  1990-02       Impact factor: 44.544

4.  Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I-II study in combination with DTIC.

Authors:  G R McLeod; D B Thomson; P Hersey
Journal:  Int J Cancer Suppl       Date:  1987

5.  Hemorrhagic metastatic intracranial neoplasms: clinical-computed tomographic correlations.

Authors:  L A Weisberg
Journal:  Comput Radiol       Date:  1985 Mar-Apr

6.  Effect of surgical treatment on stage IV melanoma.

Authors:  M A Hena; L J Emrich; R N Nambisan; C P Karakousis
Journal:  Am J Surg       Date:  1987-03       Impact factor: 2.565

7.  Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma.

Authors:  R S Aroney; J Aisner; M N Wesley; M Y Whitacre; D A Van Echo; R G Slawson; P H Wiernik
Journal:  Cancer Treat Rep       Date:  1983 Jul-Aug
  7 in total
  5 in total

1.  Brain metastases of metastatic malignant melanoma: response to DTIC and interferon-gamma.

Authors:  D Schadendorf; M Worm; B M Czarnetzki
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

2.  Intrathecal IgM response in disseminated cerebrospinal metastasis from malignant melanoma.

Authors:  M Weller; A Stevens; N Sommer; H Wiethölter
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

3.  Multiple intracranial melanoma metastases treated with surgery and radiosurgery with long term control. A case report.

Authors:  I Fedorcsák; L Sipos; A Horváth; G Kontra; L Bognár; E Osztie
Journal:  J Neurooncol       Date:  1993-05       Impact factor: 4.130

4.  Intermittent interferon and polychemotherapy in metastatic melanoma.

Authors:  M S Vuoristo; P Gröhn; P Kellokumpu-Lehtinen; E Kumpulainen; M Turunen; M Korpela; H Joensuu; K Tiusanen; A Nevantaus
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

5.  Cerebral melanoma metastases: a critical review on diagnostic methods and therapeutic options.

Authors:  Carlos R Goulart; Tobias Alecio Mattei; Ricardo Ramina
Journal:  ISRN Surg       Date:  2011-05-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.